卵巢癌组织中miR-410、CCNB1的表达及临床意义

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (611 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression levels of microRNA-410 (miR-410) and cyclin B1 (CCNB1) in ovarian cancer, and to analyze their relationship with clinical pathological data. Methods Quantitative real-time PCR (qRT-PCR) was used to detect the relative expression of miR-410 and CCNB1 mRNA in 83 cases of ovarian cancer and adjacent tissues in General Hospital of the Northern Theater of the Chinese People’s Liberation Army (from January 2017 to February 2020), the relationship between the two indicators and clinical pathological data was analyzed. Results The relative expression of miR-410 in ovarian cancer was lower than in adjacent tissues, and the relative expression of CCNB1 mRNA was higher than in adjacent tissues (P ＜ 0.05). The relative expression of miR-410 in ovarian cancer tissues in FIGO stage Ⅲ-Ⅳ, tumor invasion depth T3+T4, low-medium cell differentiation, and lymph node metastasis was lower than those of tumor FIGO stage Ⅰ-Ⅱ, tumor invasion depth T1+T2, patients with high cell differentiation and had no lymph node metastasis, and the relative expression of CCNB1 in the tumor FIGO stage Ⅲ-Ⅳ, the tumor infiltration depth was T3+T4, the cell differentiation was low to medium, and the lymph node metastasis was higher than those of the tumor FIGO stage Ⅰ-Ⅱ, the depth of tumor invasion was T1+ T2, and the cells were highly differentiated and had no lymph node metastasis (P ＜ 0.05). Correlation analysis showed that there was a negative correlation between miR-410 and CCNB1 expression in ovarian cancer (r = -0.605, P ＜ 0.05). Conclusion The expression level of miR-410 in ovarian cancer is lower than that in adjacent tissues, and the expression level of CCNB1 mRNA is higher than in adjacent tissues, which is closely related to the tumor FIGO stage, tumor invasion depth, cell differentiation degree and lymphatic metastasis. It is expected to become an biomarkers for ovarian cancer diagnosis, treatment and prognosis.

Key words： Ovarian cancer miR-410 Cyclin B1 Lymphatic metastasis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Shuang SUN Jingli

Cite this article:

ZHAO Shuang SUN Jingli. Expression and clinical significance of miR-410 and CCNB1 in ovarian cancer tissues[J]. 中国医药导报, 2021, 18(11): 105-108.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I11/105

[1] Stewart C，Ralyea C，Lockwood S. Ovarian Cancer： An Integrated Review[J]. Semin Oncol Nurs，2019，35（2）：151-156.
[2] 韦欣仪，程晓东，吕卫国.长链非编码RNA在卵巢癌转移中的研究进展[J].现代妇产科进展，2020，29（12）：956-958，960.
[3] 徐婷，姜旖，袁琳，等.初治卵巢子宫内膜异位症恶变的危险因素研究[J].现代妇产科进展，2020，29（12）：901-904.
[4] 储昭阳，朱向明，李国杰，等.COL8A1表达与上皮性卵巢癌进展和预后关系分析[J].社区医学杂志，2020，18（22）：1516-1522.
[5] 朱静，张龙辉，谢荣凯.miR-409-3p在卵巢浆液性癌中的表达及对HO-8910细胞生物学特性的影响[J].第三军医大学学报，2020，42（22）：2244-2250.
[6] 尚莹莹，邵莹，邓花娟.miR-876-5p通过靶向FBXO31促进卵巢癌细胞增殖和侵袭的机制[J].解剖学研究，2020， 42（5）：422-427.
[7] 苗培田，佟仲生，王磊.miR-122-5p靶向切除修复交叉互补1对卵巢癌细胞生物学行为的影响[J].中国临床药理学杂志，2020，36（18）：2856-2860.
[8] 黄红丽，李静，宋玉，等.ΜiR-202靶向调节EGFR介导的PI3K/AKT信号通路在紫杉醇治疗卵巢癌中的机制研究[J].肿瘤学杂志，2020，26（9）：803-807.
[9] 褚冬梅，赵振钏，刘荣霞，等.miR-410通过靶向Snail1抑制宫颈癌细胞的迁移和侵袭[J].免疫学杂志，2020，36（6）：510-515.
[10] 张庆金，关若洪，张安文，等.miR-410可促进骨髓间充质干细胞定向分化为软骨细胞[J].中国组织工程研究，2019，23（1）：13-17.
[11] Santala S，Talvensaari-Mattila A，Soini Y，et al. Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma [J]. Tumour Biol，2015，36（2）：953-957.
[12] 谷军生.miR-144靶向细胞周期蛋白B1抑制肝癌增殖、迁移和侵袭的初步研究[D].郑州：郑州大学，2016.
[13] 陈洪英，周娟.MiR-410靶向CCNB1抑制肾透明细胞癌增殖的研究[J].锦州医科大学学报，2019，40（6）：9-12， 123-124.
[14] Zhang L，Volinia S，Bonome T，et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer [J]. Proc Natl Acad Sci USA，2008，105（19）：7004-7009.
[15] 祁青玲，王烈宏，曾慧.微小RNA-375靶向ERBB2表达及对卵巢癌细胞侵袭迁移的影响[J].临床肿瘤学杂志，2020，25（9）：809-815.
[16] 徐洁欢，廉萍，叶枫.miRNA在卵巢癌组织中的表达及临床意义研究进展[J].医学理论与实践，2020，33（17）：2815-2817.
[17] 胡立华，张鉴颖，陈鹏，等.微小RNA-22在食管癌患者血清中的表达与临床意义[J].中国现代医生，2020，58（24）：13-16.
[18] 朱彩华，曹新广，吕慧芳，等.miR-374a和miR-548b调控非小细胞肺癌对吉非替尼耐药的研究[J].医药论坛杂志，2016，37（4）：1-3，7.
[19] 张倩，孙永红，文世民，等.miRNA-675-5p与食管鳞癌上皮间质转化的相关性研究[J].中国医药导报，2020， 17（4）：18-22.
[20] 简跃，王枫，刘丽丽.miR-410对上皮性卵巢癌生物学行为影响及调控作用的实验研究[J].现代妇产科进展，2020，29（1）：11-14，18.
[21] Wang W，He Y，Rui J，et al. miR-410 acts as an oncogene in colorectal cancer cells by targeting dickkopf-related protein 1 via the Wnt/β-catenin signaling pathway [J]. Oncol Lett，2019，17（1）：807-814.
[22] Liu C，Zhang A，Cheng L，et al. miR-410 regulates apoptosis by targeting Bak1 in human colorectal cancer cells [J]. Mol Med Rep，2016，14（1）：467-473.
[23] 王璐，封全灵，史惠蓉.细胞周期蛋白B1在卵巢癌中的研究进展[J].国际妇产科学杂志，2008，35（1）：44-46.
[24] 冷远秀，徐林，陈芳，等.细胞周期蛋白B1在恶性肿瘤中的研究进展[J/OL].重庆医科大学学报：1-4.
[25] Ersv?覸r E，Kildal W，Vlatkovic L，et al. Prognostic value of mitotic checkpoint protein BUB3， cyclin B1， and pituitary tumor-transforming 1 expression in prostate cancer [J]. Mod Pathol，2020，33（5）：905-915.
[26] 文志华，宋小兵，江普查，等.脑胶质瘤中凋亡抑制生存基因和细胞周期蛋白b1的表达及临床意义[J].检验医学与临床，2016，13（6）：765-767.
[27] 方益锋.Chk1介导的CCNB1高表达在结直肠癌中的作用及机制研究[D].杭州：浙江大学，2016.
[28] 康连杰，郭胜香，董昂.宫颈上皮病变中高危型HPV感染与病变分级及P53、p16INK4a和细胞周期蛋白表达的关系[J].临床和实验医学杂志，2020，19（4）：391-394.